Clinical Trials Directory

Trials / Completed

CompletedNCT02788357

Post-stroke Neural Plasticity With Atomoxetine

Enhancement of Post-stroke Neural Plasticity With Atomoxetine: a Pilot Study

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Lumy Sawaki · Academic / Other
Sex
All
Age
21 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This proposal evaluates the safety and effectiveness of a noradrenergic drug named atomoxetine combined with motor training to enhance cortical plasticity and improve hand function after stroke.

Detailed description

Extensive studies in laboratory animals and humans over the last ten years indicate that some medications, especially amphetamine, given with specific physical therapy may improve motor learning (and therefore recovery from stroke) more than physical therapy alone. However, the number of patients in clinical trials who have received physical therapy and amphetamine is very small, for two reasons: because amphetamine may interact with many other medications that stroke patients are already taking, and because its potential for addiction precludes its use on a daily basis. The investigators now wish to evaluate the effectiveness of a more selective medication, atomoxetine, known to have many fewer side effects and no potential for drug addiction. The proposed mechanism by which amphetamine enhances recovery is by increasing central levels of norepinephrine. While the investigators already know that this drug is more selective than amphetamine, the investigators would like to evaluate its effects on hand motor learning and motor recovery in chronic stroke patients in a clinical setting.

Conditions

Interventions

TypeNameDescription
DRUGAtomoxetineSubjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
DRUGPlaceboSubjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.

Timeline

Start date
2006-11-01
Primary completion
2012-12-01
Completion
2014-12-01
First posted
2016-06-02
Last updated
2017-08-14
Results posted
2017-08-14

Source: ClinicalTrials.gov record NCT02788357. Inclusion in this directory is not an endorsement.